Cargando…

Baicalin regulates the dopamine system to control the core symptoms of ADHD

We aimed to test the therapeutic effects of baicalin on attention deficit hyperactivity disorder (ADHD) in an animal model and to explain the potential mechanism. We investigated the therapeutic effects and mechanisms of baicalin in a spontaneously hypertensive rat (SHR) model of ADHD depending on t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Rongyi, Wang, Jiaojiao, Han, Xinmin, Ma, Bingxiang, Yuan, Haixia, Song, Yuchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368814/
https://www.ncbi.nlm.nih.gov/pubmed/30736828
http://dx.doi.org/10.1186/s13041-019-0428-5
_version_ 1783394070722248704
author Zhou, Rongyi
Wang, Jiaojiao
Han, Xinmin
Ma, Bingxiang
Yuan, Haixia
Song, Yuchen
author_facet Zhou, Rongyi
Wang, Jiaojiao
Han, Xinmin
Ma, Bingxiang
Yuan, Haixia
Song, Yuchen
author_sort Zhou, Rongyi
collection PubMed
description We aimed to test the therapeutic effects of baicalin on attention deficit hyperactivity disorder (ADHD) in an animal model and to explain the potential mechanism. We investigated the therapeutic effects and mechanisms of baicalin in a spontaneously hypertensive rat (SHR) model of ADHD depending on the dopamine (DA) deficit theory. In this study, fifty SHRs were randomly divided into five groups: methylphenidate (MPH), baicalin (50 mg/kg, 100 mg/kg, or 150 mg/kg), and saline-treated. Ten Wistar Kyoto (WKY) rats were used as controls. All rats were orally administered the treatment for four weeks. Motor activity, spatial learning and memory ability were assessed with the open-field and Morris water-maze tests. The mRNA and protein levels of tyrosine hydroxylase (TH), vesicular monoamine transporter 2 (VMAT2), synaptosomal-associated protein of molecular mass 25kD (SNAP25) and synataxin 1a in synaptosomes were detected with real-time polymerase chain reaction (PCR) and Western blot. In addition, DA levels were measured in the prefrontal cortex and striatum. The results indicated that both MPH and baicalin at doses of 150 mg/kg and 100 mg/kg significantly decreased the hyperactivity and improved the spatial learning memory deficit in the SHRs and increased the synaptosomal mRNA and protein levels of TH, SNAP25, VMAT2 and synataxin 1a compared with saline treatment. MPH significantly increased DA levels in both the prefrontal cortex (PFC) and striatum, while baicalin significantly increased DA levels only in the striatum. The results of the present study showed that baicalin treatment was effective for controlling the core symptoms of ADHD. Baicalin increased DA levels only in the striatum, which suggested that baicalin may target the striatum. The increased DA levels may partially be attributed to the increased mRNA and protein expression of TH, SNAP25, VMAT2, and syntaxin 1a. Therefore, these results suggested that the pharmacological effects of baicalin were associated with the synthesis, vesicular localization, and release of DA and might be effective in treating ADHD. However, further studies are required to better understand the molecular mechanisms underlying these findings.
format Online
Article
Text
id pubmed-6368814
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63688142019-02-15 Baicalin regulates the dopamine system to control the core symptoms of ADHD Zhou, Rongyi Wang, Jiaojiao Han, Xinmin Ma, Bingxiang Yuan, Haixia Song, Yuchen Mol Brain Research We aimed to test the therapeutic effects of baicalin on attention deficit hyperactivity disorder (ADHD) in an animal model and to explain the potential mechanism. We investigated the therapeutic effects and mechanisms of baicalin in a spontaneously hypertensive rat (SHR) model of ADHD depending on the dopamine (DA) deficit theory. In this study, fifty SHRs were randomly divided into five groups: methylphenidate (MPH), baicalin (50 mg/kg, 100 mg/kg, or 150 mg/kg), and saline-treated. Ten Wistar Kyoto (WKY) rats were used as controls. All rats were orally administered the treatment for four weeks. Motor activity, spatial learning and memory ability were assessed with the open-field and Morris water-maze tests. The mRNA and protein levels of tyrosine hydroxylase (TH), vesicular monoamine transporter 2 (VMAT2), synaptosomal-associated protein of molecular mass 25kD (SNAP25) and synataxin 1a in synaptosomes were detected with real-time polymerase chain reaction (PCR) and Western blot. In addition, DA levels were measured in the prefrontal cortex and striatum. The results indicated that both MPH and baicalin at doses of 150 mg/kg and 100 mg/kg significantly decreased the hyperactivity and improved the spatial learning memory deficit in the SHRs and increased the synaptosomal mRNA and protein levels of TH, SNAP25, VMAT2 and synataxin 1a compared with saline treatment. MPH significantly increased DA levels in both the prefrontal cortex (PFC) and striatum, while baicalin significantly increased DA levels only in the striatum. The results of the present study showed that baicalin treatment was effective for controlling the core symptoms of ADHD. Baicalin increased DA levels only in the striatum, which suggested that baicalin may target the striatum. The increased DA levels may partially be attributed to the increased mRNA and protein expression of TH, SNAP25, VMAT2, and syntaxin 1a. Therefore, these results suggested that the pharmacological effects of baicalin were associated with the synthesis, vesicular localization, and release of DA and might be effective in treating ADHD. However, further studies are required to better understand the molecular mechanisms underlying these findings. BioMed Central 2019-02-08 /pmc/articles/PMC6368814/ /pubmed/30736828 http://dx.doi.org/10.1186/s13041-019-0428-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Zhou, Rongyi
Wang, Jiaojiao
Han, Xinmin
Ma, Bingxiang
Yuan, Haixia
Song, Yuchen
Baicalin regulates the dopamine system to control the core symptoms of ADHD
title Baicalin regulates the dopamine system to control the core symptoms of ADHD
title_full Baicalin regulates the dopamine system to control the core symptoms of ADHD
title_fullStr Baicalin regulates the dopamine system to control the core symptoms of ADHD
title_full_unstemmed Baicalin regulates the dopamine system to control the core symptoms of ADHD
title_short Baicalin regulates the dopamine system to control the core symptoms of ADHD
title_sort baicalin regulates the dopamine system to control the core symptoms of adhd
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368814/
https://www.ncbi.nlm.nih.gov/pubmed/30736828
http://dx.doi.org/10.1186/s13041-019-0428-5
work_keys_str_mv AT zhourongyi baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd
AT wangjiaojiao baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd
AT hanxinmin baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd
AT mabingxiang baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd
AT yuanhaixia baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd
AT songyuchen baicalinregulatesthedopaminesystemtocontrolthecoresymptomsofadhd